FDA 483 - Pfizer Inc. - September 30, 2014

An FDA inspection of Pfizer Inc. Groton Laboratories, a nonclinical laboratory, identified one observation. The observation noted that the study director failed to ensure that a protocol amendment for a toxicity study was approved and followed before the changes had already occurred. This indicates a procedural lapse in adhering to study protocols.